MX384605B - Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. - Google Patents

Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.

Info

Publication number
MX384605B
MX384605B MX2017013802A MX2017013802A MX384605B MX 384605 B MX384605 B MX 384605B MX 2017013802 A MX2017013802 A MX 2017013802A MX 2017013802 A MX2017013802 A MX 2017013802A MX 384605 B MX384605 B MX 384605B
Authority
MX
Mexico
Prior art keywords
subject
rad1901
palbociclib
combination
treatment
Prior art date
Application number
MX2017013802A
Other languages
English (en)
Other versions
MX2017013802A (es
Inventor
Gary Hattersley
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX384605(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of MX2017013802A publication Critical patent/MX2017013802A/es
Publication of MX384605B publication Critical patent/MX384605B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En este documento se describen métodos para inhibir el crecimiento tumoral o producir regresión tumoral en un sujeto administrando al sujeto una cantidad terapéuticamente eficaz de una combinación de palbociclib y RAD1901.
MX2017013802A 2015-04-29 2016-04-29 Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno. MX384605B (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201562154699P 2015-04-29 2015-04-29
US201562155451P 2015-04-30 2015-04-30
US201562158469P 2015-05-07 2015-05-07
US201562192940P 2015-07-15 2015-07-15
US201562192944P 2015-07-15 2015-07-15
US201562252085P 2015-11-06 2015-11-06
US201562252916P 2015-11-09 2015-11-09
US201562265696P 2015-12-10 2015-12-10
US201562265774P 2015-12-10 2015-12-10
US201562265663P 2015-12-10 2015-12-10
US201562265658P 2015-12-10 2015-12-10
US201662323576P 2016-04-15 2016-04-15
US201662323572P 2016-04-15 2016-04-15
PCT/US2016/030321 WO2016176666A1 (en) 2015-04-29 2016-04-29 Methods of treating cancer

Publications (2)

Publication Number Publication Date
MX2017013802A MX2017013802A (es) 2018-08-15
MX384605B true MX384605B (es) 2025-03-14

Family

ID=57198783

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2021005561A MX393599B (es) 2015-04-29 2016-04-29 Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
MX2017013801A MX384908B (es) 2015-04-29 2016-04-29 Rad1901 para usarse en el tratamiento de cáncer en sujetos con cáncer positivo a receptor de estrógeno alfa resistente a farmaco.
MX2017013802A MX384605B (es) 2015-04-29 2016-04-29 Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
MX2017013794A MX394676B (es) 2015-04-29 2016-04-29 Métodos para tratar el cáncer.
MX2021004881A MX2021004881A (es) 2015-04-29 2017-10-26 Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2021003389A MX2021003389A (es) 2015-04-29 2017-10-26 Metodos para tratar el cancer.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2021005561A MX393599B (es) 2015-04-29 2016-04-29 Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
MX2017013801A MX384908B (es) 2015-04-29 2016-04-29 Rad1901 para usarse en el tratamiento de cáncer en sujetos con cáncer positivo a receptor de estrógeno alfa resistente a farmaco.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2017013794A MX394676B (es) 2015-04-29 2016-04-29 Métodos para tratar el cáncer.
MX2021004881A MX2021004881A (es) 2015-04-29 2017-10-26 Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2021003389A MX2021003389A (es) 2015-04-29 2017-10-26 Metodos para tratar el cancer.

Country Status (14)

Country Link
US (11) US20180169101A1 (es)
EP (4) EP3288383A4 (es)
JP (9) JP6926065B2 (es)
KR (9) KR102871380B1 (es)
CN (5) CN108135177B (es)
AU (3) AU2016256471B2 (es)
BR (3) BR112017023228A2 (es)
CA (2) CA2984195C (es)
HK (3) HK1251408A1 (es)
IL (10) IL255189B2 (es)
MX (6) MX393599B (es)
RU (3) RU2745678C2 (es)
SG (4) SG11201708858WA (es)
WO (3) WO2016176666A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4035664A3 (en) 2014-03-28 2022-11-30 Duke University Treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
MX393599B (es) 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
MA46479A (fr) 2016-02-15 2019-08-14 Sanofi Sa Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP2019532934A (ja) * 2016-09-27 2019-11-14 ラジウス ヘルス，インコーポレイテッド 卵巣癌を治療するための方法
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
KR102477513B1 (ko) 2016-11-17 2022-12-16 사노피 신규 치환된 n-(3-플루오로프로필)-피롤리딘 화합물, 그의 제조 방법 및 그의 치료 용도
DK3565542T3 (da) * 2017-01-05 2024-07-01 Radius Pharmaceuticals Inc Polymorphic forms of rad1901-2hcl
MX2019010981A (es) * 2017-03-16 2020-09-07 Eisai R&D Man Co Ltd Terapias de combinacion para el tratamiento de cancer de mama.
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
EP3709997A1 (en) 2017-11-16 2020-09-23 Novartis AG Pharmaceutical combination comprising lsz102 and ribociclib
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
CN111386113A (zh) 2017-12-01 2020-07-07 诺华股份有限公司 包含lsz102和阿培利司的药物组合
WO2019199891A1 (en) * 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CN110585429B (zh) * 2018-06-12 2022-10-21 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途
KR102792490B1 (ko) * 2018-07-04 2025-04-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
AR116299A1 (es) 2018-09-07 2021-04-21 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
MA54293A (fr) * 2018-11-30 2021-10-06 Radius Pharmaceuticals Inc Élacestrant en combinaison avec de l'abemaciclib chez des femmes atteintes d'un cancer du sein
PH12021551319A1 (en) * 2018-12-06 2022-05-16 Radius Pharmaceuticals Inc Methods for treating cancer resistant to cdk4/6 inhibitors
WO2020118202A1 (en) * 2018-12-06 2020-06-11 Radius Pharmaceuticals, Inc. Methods for treating cancer in models harboring esr1 mutations
JP7590084B2 (ja) * 2018-12-12 2024-11-26 ケモセントリックス，インコーポレイティド 癌治療のためのｃｘｃｒ７阻害剤
MX2021009569A (es) 2019-02-12 2021-09-08 Radius Pharmaceuticals Inc Procesos y compuestos.
BR112021022216A2 (pt) * 2019-05-09 2021-12-28 Sanofi Sa Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
JP7616794B2 (ja) 2019-07-07 2025-01-17 オレマ ファーマシューティカルズ インク． エストロゲン受容体アンタゴニストのレジメン
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
EP4114391B1 (en) * 2020-03-06 2025-07-09 Olema Pharmaceuticals, Inc. Compositions for use in a method of treating an estrogen receptor associated cancer
IL297216A (en) * 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
IL298071A (en) * 2020-05-12 2023-01-01 Genentech Inc Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
US20230263734A1 (en) * 2020-08-05 2023-08-24 Aizant Drug Research Solutions Private Limited Solid dosage forms of palbociclib
JP2024501471A (ja) * 2020-12-14 2024-01-12 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解剤としてのテトラヒドロナフタレン誘導体を用いる乳がんを治療する方法
WO2022177843A1 (en) * 2021-02-16 2022-08-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
CN113662942B (zh) * 2021-08-19 2023-02-07 中国人民解放军陆军军医大学第一附属医院 药物组合物及其在smo突变性髓母细胞瘤中的应用
WO2023064519A1 (en) 2021-10-14 2023-04-20 Teva Pharmaceuticals International Gmbh Solid state forms of elacestrant and processes for preparation thereof
DE102021130035A1 (de) 2021-11-17 2023-05-17 USound GmbH MEMS-Schallwandler mit einer gekrümmten Kontur eines Kragarmelements
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
US12555854B2 (en) 2021-11-18 2026-02-17 Globus Medical Inc. Vacuum insulated battery
WO2024104268A1 (zh) * 2022-11-15 2024-05-23 苏州科睿思制药有限公司 艾拉司群二盐酸盐的共晶及其制备方法和用途
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법
EP4574811A1 (en) 2023-12-22 2025-06-25 Sandoz Ag Crystalline forms of elacestrant dihydrochloride
WO2025158416A1 (en) 2024-01-25 2025-07-31 Assia Chemical Industries Ltd. Solid state forms of elacestrant and processes for preparation thereof

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
EP2003203A1 (en) 1996-12-23 2008-12-17 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU752925B2 (en) 1997-09-09 2002-10-03 F. Hoffmann-La Roche Ag Fracture healing using PTHrP analogs
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP1037686B1 (en) 1997-12-11 2005-08-17 Alza Corporation Device for enhancing transdermal agent flux
AU739616B2 (en) 1997-12-11 2001-10-18 Alza Corporation Device for enhancing transdermal agent flux
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU1280701A (en) 1999-11-17 2001-05-30 Novartis Ag Iontophoretic transdermal delivery of peptides
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20010044431A1 (en) 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CA2418135C (en) 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
ATE309208T1 (de) 2000-08-23 2005-11-15 Akzo Nobel Nv 10-aryl-11h-benzo(b)fluoren-derivate und analoga als östrogene mittel
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
BR0114909A (pt) 2000-10-26 2004-02-03 Alza Corp Dispositivos de distribuição de drogas transdérmicas possuindo microprotuberâncias revestidas
WO2002085447A2 (en) 2001-04-20 2002-10-31 Alza Corporation Microprojection array having a beneficial agent containing coating
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
US6881203B2 (en) 2001-09-05 2005-04-19 3M Innovative Properties Company Microneedle arrays and methods of manufacturing the same
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
AU2002357372B2 (en) 2001-12-20 2008-11-20 Alza Corporation Skin-piercing microprojections having piercing depth control
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
EP1476178A4 (en) 2002-02-14 2009-08-26 Bayer Pharmaceuticals Corp FORMULATION STRATEGIES IN STABILIZING PEPTIDES IN ORGANIC SOLVENTS AND DRY CONDITIONS
EP1513547A4 (en) 2002-05-23 2009-11-04 Michael F Holick USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
US20050276823A1 (en) 2002-07-12 2005-12-15 Cini John K Methods and compositions for preventing oxidative degradation of proteins
MXPA05000597A (es) 2002-07-19 2005-04-28 3M Innovative Properties Co Dispositivos de microaguja y aparatos de administracion por microaguja.
AU2003273761A1 (en) 2002-10-14 2004-05-04 Novo Nordisk A/S Glucagon-like peptide-2 variants
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
CA2511966A1 (en) 2002-11-01 2004-07-22 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
WO2004058682A1 (ja) * 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
JP2007505164A (ja) 2003-06-10 2007-03-08 スミスクライン ビーチャム コーポレーション アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類
JP2007500245A (ja) 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005004842A2 (en) 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
ES2290738T3 (es) 2003-06-30 2008-02-16 Alza Corporation Procedimiento para revestir microproyecciones de perforacion de la piel.
WO2005014034A1 (en) 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
US7141544B2 (en) 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20050106227A1 (en) 2003-10-28 2005-05-19 Samuel Zalipsky Delivery of polymer conjugates of therapeutic peptides and proteins via coated microprojections
AU2004287414B2 (en) 2003-10-31 2010-11-25 Alza Corporation Self-actuating applicator for microprojection array
WO2005051456A2 (en) 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
CA2545048A1 (en) 2003-11-20 2005-06-02 Warner-Lambert Company Llc Androgen receptor modulators
AU2004292953A1 (en) 2003-11-21 2005-06-09 Alza Corporation Ultrasound assisted transdermal vaccine delivery method and system
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
EP1704161A4 (en) 2004-01-07 2011-06-08 Endorech Inc ON HELIX 12 OBJECTIVE STEROIDAL PHARMACEUTICAL PRODUCTS
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
CN1942187A (zh) 2004-04-08 2007-04-04 默克公司 作为雄激素受体调节剂的17β－乙酰胺－4－氮杂甾体化合物
RU2006143544A (ru) 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
CA2565544A1 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Benzonitrile derivatives to treat musculoskeletal frailty
AU2005244734A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
WO2005113008A1 (en) 2004-05-21 2005-12-01 Mediplex Corp. Delivery agents for enhancing mucosal absorption of therapeutic agents
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
US20090069226A1 (en) 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
CN101052398A (zh) 2004-10-29 2007-10-10 默克公司 作为雄激素受体调节剂的n－(吡啶－3－基)－2－苯基丁酰胺
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
CN101102809B (zh) 2004-11-18 2010-05-26 3M创新有限公司 涂敷微针阵列的遮蔽方法
JP2008520331A (ja) 2004-11-18 2008-06-19 トランスファーマ メディカル リミテッド 薬剤の経皮的送達のためのマイクロチャネル形成とイオントフォレーシスの組合せ
EP1838290A2 (en) 2005-01-21 2007-10-03 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
WO2006113552A2 (en) 2005-04-15 2006-10-26 Smithkline Beecham Corporation Cyanoarylamines
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
JP2008546643A (ja) 2005-06-06 2008-12-25 スミスクライン ビーチャム コーポレーション ４−置換アリールアミン誘導体および医薬組成物におけるその使用
WO2007005887A2 (en) 2005-07-01 2007-01-11 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds, compositions and uses thereof
US20070021216A1 (en) 2005-07-19 2007-01-25 Sony Ericsson Mobile Communications Ab Seamless gaming method and apparatus
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
WO2007061781A1 (en) 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
CA2635251A1 (en) 2005-12-28 2007-07-26 Alza Corporation Stable therapeutic formulations
AU2007225056A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
WO2007124409A2 (en) 2006-04-20 2007-11-01 Velocys, Inc. Process for treating and/or forming a non-newtonian fluid using microchannel process technology
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
EP2010150A2 (en) 2006-04-20 2009-01-07 Amgen Inc. Stable emulsion formulations
CN101085743B (zh) 2006-06-06 2012-02-15 浙江大德药业集团有限公司 含氟烷氧基康普立停衍生物及制法和用途
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EA024161B1 (ru) 2006-07-12 2016-08-31 Юниверсити Оф Теннесси Рисерч Фаундейшн Фармацевтические композиции, содержащие замещенные ациланилиды
CA2660570C (en) 2006-08-24 2016-08-09 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
CA2658511C (en) 2006-08-25 2019-02-19 Ares Trading S.A. Use of fgf-18 compound to treat cartilage disorders
CN1927815A (zh) 2006-09-25 2007-03-14 天津理工大学 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途
EP2073789B8 (en) 2006-10-03 2023-02-08 Radius Health, Inc. A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
ES2473620T3 (es) 2007-02-06 2014-07-07 Hisamitsu Pharmaceutical Co., Inc. Dispositivo de microagujas para el diagnóstico de una alergia
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
CA2686093C (en) 2007-04-16 2018-05-08 Corium International, Inc. Solvent-cast microneedle arrays containing active
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
CA2688049A1 (en) * 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
JP2010529479A (ja) 2007-06-12 2010-08-26 シェーリング コーポレイション ＦＴＩ感受性に対するヒストンＨ２Ａｘ（ＨＨ２Ａｘ）バイオマーカー
EP2155226A4 (en) 2007-06-14 2010-07-28 Univ California COMPOUNDS FOR INHIBITING THE PROTEIN AGGREGATION AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20120150023A1 (en) 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
JP5559054B2 (ja) 2007-09-28 2014-07-23 ザ クイーンズ ユニヴァーシティ オブ ベルファスト 送達装置および方法
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
EP2052736A1 (en) 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
US8642532B2 (en) 2007-11-16 2014-02-04 Guohan Yang Excipients for protein stabilization
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
WO2009137104A1 (en) * 2008-05-09 2009-11-12 Radius Health, Inc. Combination therapy for breastcancer comprising an antiestrogenic agent
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
CN102281865B (zh) 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
CA2742659C (en) 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
EP3300765A1 (en) 2008-11-18 2018-04-04 3M Innovative Properties Co. Hollow microneedle array
WO2010074239A1 (ja) 2008-12-26 2010-07-01 久光製薬株式会社 マイクロニードルデバイス
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
CA2759850C (en) 2009-04-24 2019-10-22 Corium International, Inc. Methods for manufacturing microprojection arrays
CN102497909B (zh) 2009-07-31 2014-10-29 3M创新有限公司 中空微针阵列
WO2011051916A2 (en) 2009-11-02 2011-05-05 Universite De Geneve Stabilized protein formulations and use thereof
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
CN101912600B (zh) 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
ES2719595T3 (es) 2010-05-04 2019-07-11 Corium Int Inc Método y dispositivo para la administración transdérmica de la hormona paratiroidea usando una matriz de microproyección
US9693950B2 (en) 2010-05-28 2017-07-04 3M Innovative Properties Company Aqueous formulations for coating microneedle arrays
KR101731008B1 (ko) * 2010-06-16 2017-04-27 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
EP2680871A4 (en) 2011-03-01 2015-04-22 Sloan Kettering Inst Cancer SYMBOLS HORMONE ANALOGUE, COMPOSITIONS THEREOF AND USES THEREOF
CA2833571A1 (en) 2011-04-22 2012-10-26 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
AU2012345768B2 (en) 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
GB201217439D0 (en) 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
CN104436194B (zh) 2013-09-18 2018-03-30 北京大学 具有协同增效作用的抗癌组合物
EP3099305B1 (en) * 2014-01-27 2025-11-19 Dna Seq 2, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
JP2017507964A (ja) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
EP4035664A3 (en) * 2014-03-28 2022-11-30 Duke University Treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
MX393599B (es) * 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco

Also Published As

Publication number Publication date
KR20250152678A (ko) 2025-10-23
CN108024540A (zh) 2018-05-11
SG11201708858WA (en) 2017-11-29
IL319266A (en) 2025-04-01
HK1251408A1 (zh) 2019-02-01
EP3294065A1 (en) 2018-03-21
JP2018514593A (ja) 2018-06-07
IL255189A0 (en) 2017-12-31
BR112017023269A2 (en) 2018-11-06
JP7146992B2 (ja) 2022-10-04
AU2016256471A1 (en) 2017-12-21
EP3288383A4 (en) 2019-01-23
JP2018514549A (ja) 2018-06-07
IL255261B1 (en) 2023-11-01
IL307981B1 (en) 2025-11-01
RU2017140676A (ru) 2019-05-29
US20180169101A1 (en) 2018-06-21
EP3288383A1 (en) 2018-03-07
AU2016256470B2 (en) 2020-10-15
CA2984200C (en) 2024-03-19
IL255189B1 (en) 2023-12-01
US11819480B2 (en) 2023-11-21
US20220339126A1 (en) 2022-10-27
IL307981A (en) 2023-12-01
IL255189B2 (en) 2024-04-01
NZ737825A (en) 2024-10-25
AU2016256469A8 (en) 2017-12-21
RU2747228C2 (ru) 2021-04-29
CN113288887A (zh) 2021-08-24
WO2016176664A1 (en) 2016-11-03
KR102871408B1 (ko) 2025-10-14
WO2016176665A1 (en) 2016-11-03
JP7019422B2 (ja) 2022-02-15
JP7696378B2 (ja) 2025-06-20
US20200368183A1 (en) 2020-11-26
MX2021005561A (es) 2022-07-01
HK1251409A1 (zh) 2019-02-01
CA2984195A1 (en) 2016-11-03
MX394676B (es) 2025-03-24
US20180214393A1 (en) 2018-08-02
JP7745708B2 (ja) 2025-09-29
US12263141B2 (en) 2025-04-01
JP2021105064A (ja) 2021-07-26
AU2016256469B2 (en) 2020-12-10
US20240091177A1 (en) 2024-03-21
BR112017023233A2 (en) 2018-11-06
IL310069B1 (en) 2025-04-01
RU2017140675A (ru) 2019-05-29
CA2984195C (en) 2023-10-24
KR20250153309A (ko) 2025-10-24
IL297369B1 (en) 2024-02-01
JP2021102640A (ja) 2021-07-15
MX2017013794A (es) 2018-08-15
IL323926A (en) 2025-12-01
KR20180042155A (ko) 2018-04-25
MX393599B (es) 2025-03-19
KR20180011780A (ko) 2018-02-02
AU2016256469A1 (en) 2017-12-14
SG11201708860SA (en) 2017-11-29
KR20240095372A (ko) 2024-06-25
CN108024541B (zh) 2021-07-20
CN108024541A (zh) 2018-05-11
KR102871388B1 (ko) 2025-10-14
JP2024120996A (ja) 2024-09-05
JP2022172039A (ja) 2022-11-14
IL310069B2 (en) 2025-08-01
CN113750091B (zh) 2025-03-11
IL255148B (en) 2022-12-01
RU2745678C2 (ru) 2021-03-30
MX2017013801A (es) 2018-08-15
RU2737496C2 (ru) 2020-12-01
MX2017013802A (es) 2018-08-15
CA2984200A1 (en) 2016-11-03
CA2984357A1 (en) 2016-11-03
US20200046655A1 (en) 2020-02-13
KR20240097966A (ko) 2024-06-27
EP3288382A1 (en) 2018-03-07
EP4039253A1 (en) 2022-08-10
SG10202104177VA (en) 2021-05-28
IL307983A (en) 2023-12-01
US20250367141A1 (en) 2025-12-04
JP7516472B2 (ja) 2024-07-16
JP2025170141A (ja) 2025-11-14
AU2016256470A1 (en) 2017-12-14
KR102871380B1 (ko) 2025-10-14
KR102676629B1 (ko) 2024-06-18
KR20250152679A (ko) 2025-10-23
US20200038343A1 (en) 2020-02-06
JP6926065B2 (ja) 2021-08-25
IL255148B2 (en) 2023-04-01
US11413258B2 (en) 2022-08-16
KR20240110098A (ko) 2024-07-12
JP2023052631A (ja) 2023-04-11
KR102682763B1 (ko) 2024-07-05
RU2017140674A3 (es) 2019-09-27
WO2016176666A1 (en) 2016-11-03
CN108135177A (zh) 2018-06-08
JP7262508B2 (ja) 2023-04-21
IL297369A (en) 2022-12-01
AU2016256471B2 (en) 2020-09-10
SG11201708861VA (en) 2017-11-29
MX2021004881A (es) 2021-07-21
MX384908B (es) 2025-03-14
NZ737822A (en) 2024-10-25
EP3294065A4 (en) 2019-03-20
EP3288382A4 (en) 2019-01-30
IL255148A0 (en) 2017-12-31
IL307983B1 (en) 2025-11-01
JP6926066B2 (ja) 2021-08-25
CN108135177B (zh) 2021-06-01
JP2018518529A (ja) 2018-07-12
IL255261A0 (en) 2017-12-31
US20240099996A1 (en) 2024-03-28
IL323924A (en) 2025-12-01
US20250367140A1 (en) 2025-12-04
RU2017140674A (ru) 2019-05-29
CN108024540B (zh) 2021-09-17
KR20180043202A (ko) 2018-04-27
IL297369B2 (en) 2024-06-01
BR112017023228A2 (en) 2018-11-06
NZ737819A (en) 2024-10-25
RU2017140675A3 (es) 2019-09-27
US20220110890A1 (en) 2022-04-14
IL310069A (en) 2024-03-01
RU2017140676A3 (es) 2019-09-27
CN113750091A (zh) 2021-12-07
MX2021003389A (es) 2021-05-28
KR102676705B1 (ko) 2024-06-18
US20180153828A1 (en) 2018-06-07
IL255261B2 (en) 2024-03-01
HK1251407A1 (zh) 2019-02-01

Similar Documents

Publication Publication Date Title
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MY186977A (en) Tetrasubstituted alkene compounds and their use
JO3589B1 (ar) مثبطات كيناز البروتين c وطرق استخداماتها
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX2017000168A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
MX2016007585A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
CO2017000359A2 (es) Compuestos derivados de piridina sustituidos como inhibidores de histonas desmetilasa
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MX2023011187A (es) Metodos para tratar el cancer de prostata.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
IN2014MU00303A (es)
IL270716A (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
IL269357A (en) Combination therapies for the treatment of breast cancer
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
IL284981A (en) Semaphorin-4d antagonists for use in cancer therapy
BR112019025164A2 (pt) Esquema de dosagem para tesetaxel e capecitabina
IL252639A0 (en) Breast cancer treatment using taxane
SI3856774T1 (sl) Postopki zdravljenja rezidualnega raka dojke s trastuzumab emtanzinom
EA201990411A1 (ru) Способы лечения рака предстательной железы
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds